Illumina expands GoldenGate genotyping portfolio with launch of new products

By E. Janene Geiss

Philadelphia, March 7 - Illumina, Inc. announced Tuesday the commercial availability of three new GoldenGate single nucleotide polymorphism (SNP) assay panels designed to study genetic variation and help researchers understand how certain genotypes impact disease.

Illumina also introduced a 96-plex Sentrix universal array, further expanding the multiplexing flexibility of custom GoldenGate genotyping. Along with the catalog offerings, the company also released a new test panel to screen DNA samples for predictive assay quality, according to a company news release.

Developed in collaboration with the National Cancer Institute, Illumina's new Cancer SNP panel can genotype 1421 loci on more than 400 genes thought to be related to disease progression. As a result of the implementation on the Sentrix Array Matrix format, 96 samples are analyzed in parallel. This panel gives cancer researchers an effective tool for conducting candidate gene-based association studies across many samples, officials said.

Illumina said it also offers the two mouse linkage panels for high-throughput and highly informative GoldenGate genotyping. The first panel includes 377 validated SNP loci optimized for the 10 most common inbred mouse strains used in genetic mapping. The second panel (1449 loci) provides higher resolution and broader mapping capability, enabling linkage analysis in outbred strains as well.

"Customers will find it very easy to integrate these SNP panels into their BeadStation genotyping operations," Sarah Shaw Murray, staff genotyping science manager, said in the release.

The company released another new product line, the Sentrix universal arrays, which contain a multiplex level of just 96 GoldenGate assays. This advancement now allows customers flexibility to genotype sets of custom markers ranging from 96 to 1536 SNPs per array, depending on their application and need, officials said.

Illumina also has developed and made available a GoldenGate DNA test panel comprised of more than 360 markers that reside outside of genes and conserved sequences and are likely to be "neutral" to disease association. This panel can be used to selectively pre-screen sample DNA quality prior to embarking on a large-scale genotyping study.

The company's genotyping product portfolio includes custom and standard products, with focused and whole-genome content, deployed on two different array platforms: the 96-sample Sentrix Array Matrix and the high-density Sentrix BeadChip.

Illumina is a San Diego biopharmaceutical company that develops next-generation tools that permit large-scale analysis of genetic variation and function.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.